Table 3.
Antitumor efficacy of treatment groups in a SKOV3 cell-bearing xenograft mouse model
| Treatment group | Dose (mg/kg) | Number of animals (start/end) | Average tumor weight (g) | TGI (%) |
|---|---|---|---|---|
| Saline | – | 5/5 | 3.53±1.46 | – |
| DTX-Sol | 10 | 5/5 | 1.37±0.92* | 61.39 |
| DTX-NLC | 10 | 5/5 | 0.46±0.28* | 86.94 |
| DTX-RIPL-NLC | 10 | 5/5 | 0.31±0.15*,# | 91.24 |
Notes: Data are mean ± SD (n=3).
*
P<0.05 versus saline;
#
P<0.05 versus DTX-Sol.
Abbreviations: DTX-Sol, docetaxel solution; DTX-NLC, docetaxel-loaded nanostructured lipid carrier; DTX-RIPL-NLC, docetaxel-loaded RIPL peptide-conjugated nanostructured lipid carrier; TGI, tumor growth inhibition.